Skip to main content

Journey Medical Corporation

corporate_fare Company Profile

Journey Medical Corporation

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed DERM - Latest Insights

DERM
Apr 21, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
DERM
Mar 25, 2026, 6:09 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
DERM
Mar 25, 2026, 5:35 PM EDT
Filing Type: 10-K
Importance Score:
9
DERM
Mar 25, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
DERM
Jan 23, 2026, 4:06 PM EST
Filing Type: 424B3
Importance Score:
8
DERM
Jan 15, 2026, 4:43 PM EST
Filing Type: S-3
Importance Score:
9